{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:07Z","timestamp":1786979827158,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Rani Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03969-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:53:14Z","timestamp":1768801994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants"],"prefix":"10.1007","volume":"82","author":[{"given":"Joshua T.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Horlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April Toledo","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hoopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer M.","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir A.","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvinder K.","family":"Dhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"9","key":"3969_CR1","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1345\/aph.1M151","volume":"43","author":"JV Scanlon","year":"2009","unstructured":"Scanlon JV, Exter BP, Steinberg M, Jarvis CI (2009) Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother 43(9):1456\u20131465. https:\/\/doi.org\/10.1345\/aph.1M151","journal-title":"Ann Pharmacother"},{"key":"3969_CR2","first-page":"11","volume":"5","author":"E Krulig","year":"2010","unstructured":"Krulig E, Gordon KB (2010) Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 5:11\u201322","journal-title":"Core Evid"},{"issue":"12","key":"3969_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/jdv.12046","volume":"27","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H et al (2013) Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 27(12):1535\u20131545. https:\/\/doi.org\/10.1111\/jdv.12046","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3969_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3390\/pharmaceutics15051415","volume":"15","author":"S Masloh","year":"2023","unstructured":"Masloh S, Culot M, Gosselet F, Chevrel A, Scapozza L, Zeisser Labouebe M (2023) Challenges and opportunities in the oral delivery of recombinant biologics. Pharmaceutics 15(5):1415\u20131459. https:\/\/doi.org\/10.3390\/pharmaceutics15051415","journal-title":"Pharmaceutics"},{"key":"3969_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ijwd.2020.09.012","volume":"10","author":"Y Goenaga-V\u00e1zquez","year":"2020","unstructured":"Goenaga-V\u00e1zquez Y, Lauck KC, Hebert AA (2020) Therapeutic challenges in managing pediatric psoriasis. Int J Womens Dermatol 10:314\u2013318. https:\/\/doi.org\/10.1016\/j.ijwd.2020.09.012","journal-title":"Int J Womens Dermatol"},{"issue":"6","key":"3969_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129120","volume":"9","author":"C Kromer","year":"2015","unstructured":"Kromer C, Schaarschmidt ML, Schmieder A, Herr R, Goerdt S, Peitsch WK (2015) Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One 9(6):e0129120","journal-title":"PLoS One"},{"key":"3969_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.36469\/9817","volume":"4","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Moeller AH, Erntoft Idemyr ST, Gonz\u00e1lez JM (2016) Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. Jheor 4:141\u2013157","journal-title":"Jheor"},{"key":"3969_CR8","first-page":"938","volume":"9","author":"M DiBonaventura","year":"2010","unstructured":"DiBonaventura M, Wagner S, Waters H, Carter C (2010) Treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with psoriasis. J Drugs Dermatol 9:938\u2013944","journal-title":"J Drugs Dermatol"},{"key":"3969_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/24755303241253200","volume":"9","author":"M Zaino","year":"2024","unstructured":"Zaino M, Parks E, McNeil J, Feldman S (2024) Patients\u2019 preferences regarding modes of systemic psoriasis treatment - a qualitative study. J Psoriasis Psoriatic Arthritis 9:136\u2013142. https:\/\/doi.org\/10.1177\/24755303241253200","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"3969_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s13555-023-01089-6","volume":"14","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Jayade S, Rege S et al (2024) Evaluating treatment choice in patients with moderate to severe psoriasis in the united states: results from a US patient survey. Dermatol Therapy 14:421\u2013439. https:\/\/doi.org\/10.1007\/s13555-023-01089-6","journal-title":"Dermatol Therapy"},{"key":"3969_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/ppa.S463354","volume":"18","author":"JT Myers","year":"2024","unstructured":"Myers JT, Van Dam J, Imran M, Hashim M, Dhalla AK (2024) Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adherence 18:1547\u20131562. https:\/\/doi.org\/10.2147\/ppa.S463354","journal-title":"Patient Prefer Adherence"},{"key":"3969_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coph.2017.07.003","volume":"36","author":"E Caffarel-Salvador","year":"2017","unstructured":"Caffarel-Salvador E, Abramson A, Langer R, Traverso G (2017) Oral delivery of biologics using drug-device combinations. Curr Opin Pharmacol 36:8\u201313. https:\/\/doi.org\/10.1016\/j.coph.2017.07.003","journal-title":"Curr Opin Pharmacol"},{"key":"3969_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Gokarn Y, Mitragotri S (2019) Non-invasive delivery strategies for biologics. Nat Rev Drug Discovery 18:19\u201340","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"3969_CR14","doi-asserted-by":"publisher","first-page":"e00522","DOI":"10.1002\/prp2.522","volume":"7","author":"M Hashim","year":"2019","unstructured":"Hashim M, Korupolu R, Syed B et al (2019) Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A Pharmacokinetic and pharmacodynamic study. Pharmacol Res Perspect 7(5):e00522. https:\/\/doi.org\/10.1002\/prp2.522","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"3969_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s13346-021-00938-1","volume":"12","author":"AK Dhalla","year":"2022","unstructured":"Dhalla AK, Al-Shamsie Z, Beraki S et al (2022) A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects. Drug Delivery Translational Res 12(1):294\u2013305. https:\/\/doi.org\/10.1007\/s13346-021-00938-1","journal-title":"Drug Delivery Translational Res"},{"key":"3969_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fddev.2022.955569\/full","volume":"2","author":"A Yamaguchi","year":"2022","unstructured":"Yamaguchi A, Van Dam J, Dhalla AK et al (2022) Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines. Front Drug Delivery 2:1\u201312. https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fddev.2022.955569\/full","journal-title":"Front Drug Delivery"},{"key":"3969_CR17","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/cphy.c150049","volume":"6","author":"GF Gebhart","year":"2016","unstructured":"Gebhart GF, Bielefeldt K (2016) Physiology of visceral pain. Compr Physiol 6:1609\u20131633. https:\/\/doi.org\/10.1002\/cphy.c150049","journal-title":"Compr Physiol"},{"key":"3969_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/pharmaceutics13010018","volume":"13","author":"R New","year":"2021","unstructured":"New R (2021) Oral delivery of biologics via the intestine. Pharmaceutics 13:18\u201339","journal-title":"Pharmaceutics"},{"key":"3969_CR19","doi-asserted-by":"publisher","unstructured":"Vo AT, Yamaguchi A, Dhalla A, Horlen K, Fung L, Syed B et al (2023) Oral delivery of a GLP-1 agonist with high bioavailability in dogs and humans. Diabetes 72(Suppl 1). https:\/\/doi.org\/10.2337\/db23-89-LB","DOI":"10.2337\/db23-89-LB"},{"key":"3969_CR20","doi-asserted-by":"publisher","unstructured":"Horlen K, Yamaguchi A, Vo AT, Kaminskaya K, Fung LC, May L et al (2024) Orally administered ustekinumab biosimilar delivered via a robotic pill yields bioavailability comparable to subcutaneous injection in canines. Gastroenterology 166(5). https:\/\/doi.org\/10.3390\/pharmaceutics13010018","DOI":"10.3390\/pharmaceutics13010018"},{"key":"3969_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70064","author":"JT Myers","year":"2025","unstructured":"Myers JT, Yamaguchi A, Vo AT et al (2025) An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: a phase 1 study. Br J Clin Pharmacol. https:\/\/doi.org\/10.1002\/bcp.70064","journal-title":"Br J Clin Pharmacol"},{"key":"3969_CR22","first-page":"220","volume":"16","author":"M Zhang","year":"2017","unstructured":"Zhang M, Carter C, Olson WH, Johnson MP, Brenneman SK, Lee S, Farahi K (2017) Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol 16:220\u2013226","journal-title":"J Drugs Dermatol"},{"key":"3969_CR23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/jcm11061506","volume":"11","author":"E Piragine","year":"2022","unstructured":"Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E et al (2022) Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med 11:1506\u20131524. https:\/\/doi.org\/10.3390\/jcm11061506","journal-title":"J Clin Med"},{"key":"3969_CR24","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","volume":"39","author":"C Leonardi","year":"2022","unstructured":"Leonardi C, Zhu B, Malatestinic WN, Eastman WJ, Guo J et al (2022) Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM Marketscan\u00ae databases. Adv Ther 39:3214\u20133224. https:\/\/doi.org\/10.1007\/s12325-022-02155-9","journal-title":"Adv Ther"},{"key":"3969_CR25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","volume":"33","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR (2022) Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat 33:2270\u20132277. https:\/\/doi.org\/10.1080\/09546634.2021.1950600","journal-title":"J Dermatolog Treat"},{"key":"3969_CR26","unstructured":"Stelara [package insert] (2020) Janssen Biotech, Inc USA"},{"key":"3969_CR27","unstructured":"Hashim MA, Yamaguchi A, Vo AT, Dhalla AK, Syed B et al (2021) Orally delivered factor VIII restores hemostasis in a hemophilia a dog. Res Pract Thromb Hemostasis 5(Suppl 2)"},{"key":"3969_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/a:1015880819328","volume":"7","author":"A Supersaxo","year":"1990","unstructured":"Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167\u2013169. https:\/\/doi.org\/10.1023\/a:1015880819328","journal-title":"Pharm Res"},{"key":"3969_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","volume":"2","author":"DN McLennan","year":"2005","unstructured":"McLennan DN, Porter CJH, Charman SA (2005) Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2:89\u201396. https:\/\/doi.org\/10.1016\/j.ddtec.2005.05.006","journal-title":"Drug Discov Today Technol"},{"key":"3969_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(sici)1520-6017(200003)89:3<297::Aid-jps2>3.0.Co;2-p","volume":"89","author":"CJ Porter","year":"2000","unstructured":"Porter CJ, Charman SA (2000) Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297\u2013310. https:\/\/doi.org\/10.1002\/(sici)1520-6017(200003)89:3%3C;297::Aid-jps2%3E;3.0.Co;2-p","journal-title":"J Pharm Sci"},{"key":"3969_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.physbeh.2011.04.056","volume":"105","author":"AB Kohan","year":"2011","unstructured":"Kohan AB, Yoder SM, Tso P (2011) Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones. Physiol Behav 105:82\u201388. https:\/\/doi.org\/10.1016\/j.physbeh.2011.04.056","journal-title":"Physiol Behav"},{"issue":"5","key":"3969_CR32","doi-asserted-by":"publisher","DOI":"10.4142\/jvs.2021.22.e47","volume":"22","author":"T Grabowski","year":"2021","unstructured":"Grabowski T, Burmanczuk A, Derlacz R, Stefaniak T, Rzasa A, Borkowski J (2021) Ustekinumab pharmacokinetics after subcutaneous administration in swine model. J Vet Sci 22(5):e47. https:\/\/doi.org\/10.4142\/jvs.2021.22.e47","journal-title":"J Vet Sci"},{"key":"3969_CR33","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1111\/j.1749-6632.2010.05753.x","volume":"1207","author":"A Kohan","year":"2010","unstructured":"Kohan A, Yoder S, Tso P (2010) Lymphatics in intestinal transport of nutrients and gastrointestinal hormones. Ann N Y Acad Sci 1207:E44-51. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05753.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3969_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2019","unstructured":"Al Shoyaib A, Archie SR, Karamyan VT (2019) Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res 37(1):12. https:\/\/doi.org\/10.1007\/s11095-019-2745-x","journal-title":"Pharm Res"},{"key":"3969_CR35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","volume":"155","author":"T Tsakok","year":"2019","unstructured":"Tsakok T, Wilson N, Dand N, Loeff FC et al (2019) Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol 155:1235\u20131243","journal-title":"JAMA Dermatol"},{"key":"3969_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjd.18709","volume":"182","author":"N Van den Berghe","year":"2020","unstructured":"Van den Berghe N, De Keyser E, Soenen R, Meuleman L, Lanssens S et al (2020) Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. Br J Dermatol 182:271\u2013272","journal-title":"Br J Dermatol"},{"key":"3969_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.16558","volume":"35","author":"J Bagel","year":"2021","unstructured":"Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A et al (2021) Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol 35:135\u2013142. https:\/\/doi.org\/10.1111\/jdv.16558","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3969_CR38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392:650\u2013661. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6","journal-title":"Lancet"},{"key":"3969_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","volume":"82","author":"R Warren","year":"2020","unstructured":"Warren R, Gooderham M, Burge R, Zhu B, Amato D et al (2020) Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol 82:1138\u20131149","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03969-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:04:35Z","timestamp":1771859075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03969-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03969-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with the ethical standards and protocols approved by the local ethics committee. Written informed consent was obtained from all participants before being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declaration"}},{"value":"The authors confirm that the Principal Investigator for this paper is Ofer M. Gonen, MD, PhD, FRACP and had direct clinical responsibility for patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Principal investigator statement"}},{"value":"All authors, except Ofer Gonen and Andrew Blauvelt, were employees of the company at the time the work was conducted. Dr. Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company, UCB, and Almirall, has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, Leo, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Rani Therapeutics, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab, has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB, and owns stock in Lipidio and Oruka.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Therapeutic antibodies, such as ustekinumab, cannot be taken orally due to rapid degradation by digestive enzymes. Formulation strategies, such as encapsulation and targeted delivery, are under development to overcome these barriers to oral delivery of antibodies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"What is already known about this subject"}},{"value":"This study shows that a novel, orally ingestible robotic pill (RP) can protect an antibody from digestion and auto-deploy in the small intestine, delivering the biologic as a painless transenteric injection with high reliability and bioavailability, similar to a subcutaneous (SC) injection. PK simulations project that a more frequent (oral) dosing regimen will maintain steady state therapeutic exposures within a narrow range, potentially minimizing adverse effects and improving therapeutic outcomes, unlike the high peak-to-trough variability in circulating drug levels typically observed with typical SC injection dosing intervals.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"What this study adds"}}],"article-number":"40"}}